Physician profile
Shahm Martini
NPI 1962459461
$2,258.39
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $135 · 2021: $325 · 2022: $199 · 2023: $686 · 2024: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $686.59 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $557.44 | 2019-2024 | Rexulti |
| Lundbeck LLC | $195.39 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $143.02 | 2023-2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $120.76 | 2022-2024 | Quviviq |
| Tris Pharma INC | $113.55 | 2023-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $103.77 | 2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $84.19 | 2019-2020 | |
| Shire North American Group INC | $49.85 | 2019 | |
| Noven Therapeutics, LLC | $48.28 | 2024 | Xelstrym, Secuado |
| Bausch Health US, LLC | $44.29 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $41.50 | 2019 | |
| Eisai INC. | $24.40 | 2021 | |
| Vanda Pharmaceuticals INC. | $21.97 | 2019 | |
| Mdd US Operations, LLC | $12.35 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahm Martini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.